Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12106| Title: | Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. | Austin Authors: | Lim, Yen Ying;Maruff, Paul;Pietrzak, Robert H;Ellis, Kathryn A;Darby, David G;Ames, David;Harrington, Karra;Martins, Ralph N;Masters, Colin L ;Szoeke, Cassandra;Savage, Greg;Villemagne, Victor L ;Rowe, Christopher C | Institutional Author: | AIBL Research Group | Affiliation: | CogState Ltd., Melbourne, Victoria, Australia National Ageing Research Institute, Parkville, Victoria, Australia Department of Psychology and ARC Centre of Excellence in Cognition and Its Disorders, Macquarie University, Sydney, New South Wales, Australia Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Kew, Victoria, Australia Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia CSIRO Preventative Health Flagship, Parkville, Victoria, Australia Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical, and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia |
Issue Date: | 28-Feb-2014 | Publication information: | Alzheimer's & Dementia : the Journal of the Alzheimer's Association 2014; 10(6): 743-751.e1 | Abstract: | High β-amyloid (Aβ) is associated with faster memory decline in healthy individuals and adults with mild cognitive impairment (MCI). However, longer prospective studies are required to determine if Aβ-related memory decline continues and whether it is associated with increased rate of disease progression.Healthy controls (HCs; n = 177) and adults with MCI (n = 48) underwent neuroimaging for Aβ and cognitive assessment at baseline. Cognition was reassessed 18 and 36 months later.Compared with low-Aβ HCs, high-Aβ HC and MCI groups showed moderate decline in episodic and working memory over 36 months. Those with MCI with low Aβ did not show any cognitive decline. Rates of disease progression were increased in the high-Aβ HC and MCI groups.In healthy individuals, high Aβ likely indicates that Alzheimer's disease (AD)-related neurodegeneration has begun. Once commenced, the rate of decline in cognitive function remains constant across the preclinical and prodromal stages of AD. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/12106 | DOI: | 10.1016/j.jalz.2013.11.005 | Journal: | Alzheimer's & dementia : the journal of the Alzheimer's Association | URL: | https://pubmed.ncbi.nlm.nih.gov/24589436 | Type: | Journal Article | Subjects: | Aβ Cognitive decline Neuropsychology Preclinical AD Prodromal AD |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.